Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? 2012

Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
Departments of Pharmacology and Experimental Therapeutics, Boston University Medical Campus, Boston, MA 02118, USA.

Sporadic Alzheimer's disease (AD) patients have low amyloid-β peptide (Aβ) clearance in the central nervous system. The peripheral Aβ clearance may also be important but its role in AD remains unclear. We aimed to study the Aβ degrading proteases including insulin degrading enzyme (IDE), angiotensin converting enzyme (ACE) and others in blood. Using the fluorogenic substrate V (a substrate of IDE and other metalloproteases), we showed that human serum degraded the substrate V, and the activity was inhibited by adding increasing dose of Aβ. The existence of IDE activity was demonstrated by the inhibition of insulin, amylin, or EDTA, and further confirmed by immunocapture of IDE using monoclonal antibodies. The involvement of ACE was indicated by the ability of the ACE inhibitor, lisinopril, to inhibit the substrate V degradation. To test the variations of substrate V degradation in humans, we used serum samples from a homebound elderly population with cognitive diagnoses. Compared with the elderly who had normal cognition, those with probable AD and amnestic mild cognitive impairment (amnestic MCI) had lower peptidase activities. Probable AD or amnestic MCI as an outcome remained negatively associated with serum substrate V degradation activity after adjusting for the confounders. The elderly with probable AD had lower serum substrate V degradation activity compared with those who had vascular dementia. The blood proteases mediating Aβ degradation may be important for the AD pathogenesis. More studies are needed to specify each Aβ degrading protease in blood as a useful biomarker and a possible treatment target for AD.

UI MeSH Term Description Entries
D007339 Insulysin An enzyme the catalyzes the degradation of insulin, glucagon and other polypeptides. It is inhibited by bacitracin, chelating agents EDTA and 1,10-phenanthroline, and by thiol-blocking reagents such as N-ethylmaleimide, but not phosphoramidon. (Eur J Biochem 1994;223:1-5) EC 3.4.24.56. Insulinase,Insulin Protease,Insulin Proteinase,Insulin-Degrading Enzyme,Enzyme, Insulin-Degrading,Insulin Degrading Enzyme,Protease, Insulin,Proteinase, Insulin
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005260 Female Females
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic

Related Publications

Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
June 2021, Journal of molecular biology,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
February 2006, Neurobiology of aging,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
September 2018, Oncotarget,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
December 2023, Neuronal signaling,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
January 2004, Journal of molecular neuroscience : MN,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
January 2005, Neural plasticity,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
January 2018, Trends in pharmacological sciences,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
August 2023, The FEBS journal,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
January 2018, Current Alzheimer research,
Zhiheng Liu, and Haihao Zhu, and Guang Guang Fang, and Kathryn Walsh, and Mkaya Mwamburi, and Benjamin Wolozin, and Samer O Abdul-Hay, and Tsuneya Ikezu, and Malcolm A Leissring, and Wei Qiao Qiu
February 2019, Nagoya journal of medical science,
Copied contents to your clipboard!